Table 1.
Patients’ characteristics
| Patient cohortn = 865 | |
|---|---|
| Median age [range] | 56.6 years [24–74 years] |
| Sex | |
| Male | 509 (58.8%) |
| Female | 356 (41.2%) |
| MM type | |
| IgG | 486 (58.8%) |
| IgA | 174 (21.1%) |
| IgD | 16 (1.9%) |
| IgM | 1 (0.1%) |
| Bence‐Jones | 150 (18.2%) |
| double gammopathy (IgG + IgA) | 1 (0.1%) |
| asecretory | 36 (4.2%) |
| missing | 1 |
| ISS stage | |
| 1 | 249 (45.7%) |
| 2 | 169 (31.0%) |
| 3 | 127 (23.3%) |
| missing | 2 |
| Creatinine | |
| <2 mg/dL | 743 (86.2%) |
| ≥2 mg/dL | 119 (13.8%) |
| missing | 3 |
| Hemoglobin | |
| <10 g/dL | 233 (29.7%) |
| ≥10 g/dL | 551 (70.3%) |
| missing | 81 |
| Thrombocytes | |
| <150.000/μL | 75 (10.4%) |
| ≥150.000/μL | 646 (89.6%) |
| missing | 144 |
| Lactate dehydrogenase | |
| ≤upper limit of normal | 547 (82.1%) |
| >upper limit of normal | 119 (17.9%) |
| missing | 199 |
| Median β2‐microglobulin | 3.0 mg/L [2.1–4.8] |
| Median serum albumin | 40.8 g/L [35.5–44.6] |
| Induction therapy | |
| Novel agent‐based | 358 (41.7%) |
| Conventional | 500 (58.3%) |
| missing | 7 |
| Maintenance therapy | |
| No maintenance | 371 (49.0%) |
| interferon α | 265 (35.0%) |
| thalidomide | 84 (11.1%) |
| other | 37 (4.9%) |
| missing | 108 |
| Single/Tandem ASCT | |
| Single ASCT | 607 (70.2%) |
| Tandem ASCT | 258 (29.8%) |
| Year of ASCT | |
| 1992–1995 | 39 (4.5%) |
| 1996–2000 | 182 (21.0%) |
| 2001–2005 | 178 (20.6%) |
| 2006–2010 | 305 (35.3%) |
| 2011–2014 | 161 (18.6%) |
| Median time from diagnosis to first ASCT | 6.6 months [5.5–8.4] |
| Response after ASCT (EBMT) | |
| Complete response | 76 (9.4%) |
| Partial response | 652 (80.7%) |
| Minor response | 34 (4.2%) |
| Stable disease | 10 (1.2%) |
| Progressive disease | 36 (4.5%) |
| Response after ASCT (IMWG) | |
| Complete response | 15 (3.7%) |
| Near complete response | 152 (37.4%) |
| Very good partial response | 89 (21.9%) |
| Partial response | 120 (29.5%) |
| Minor response | 12 (3.0%) |
| Stable disease | 5 (1.2%) |
| Progressive disease | 14 (3.4%) |
Laboratory values assessed at time of diagnosis. For serum β2‐microglobulin, serum albumin and time from diagnosis to first ASCT median as well as first and third quartiles are given.